Curium's $7B takeover offer drives surge in Lantheus shares
Curium's $7B takeover offer drives 9% surge in Lantheus shares
- Bloomberg and Reuters reported May 22 that Lantheus is weighing sale after Curium Pharma offer valuing it at ~$7 billion
- Discussions are ongoing between the radiopharma firms and could yield a deal in coming weeks
- LNTH closed at $103.00, up $8.53 or 9.03% on the day, hitting intraday highs near $104
- Follows Q1 2026 earnings beat in early May that initially lifted shares ~6%
- Offer highlights strong interest in Lantheus' PYLARIFY imaging agent and radiopharma pipeline
- No assurance a transaction will occur, per sources familiar with private talks
- Prior analyst price targets ranged $94-$115 following recent positive developments
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.